Vani Parmar

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

Rajendra Badwe, Rohini Hawaldar, Nita Nair et al. · The Lancet Oncology · 2015 · 594 citations

Medicine, Oncology, Surgery +11

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Jürg Bernhard, Weixiu Luo, Karin Ribi et al. · The Lancet Oncology · 2015 · 179 citations · Full text

Medicine, Gynecology, Oncology +14

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Poornima Saha, Meredith M. Regan, Olivia Pagani et al. · Journal of Clinical Oncology · 2017 · 148 citations · Full text

Medicine, Endocrinology, Oncology +17

Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India

Srinath Gupta, Jaya Ghosh, S Desai et al. · Indian Journal of Cancer · 2011 · 141 citations

Medicine, Endocrinology, Oncology +13

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Karin Ribi, Weixiu Luo, Jürg Bernhard et al. · Journal of Clinical Oncology · 2016 · 128 citations · Full text

Medicine, Oncology, Breast Oncology +14